Sopharma Ltd took part in the yearly meeting of the National council of the UNGC Network Bulgaria, during which plans were made for the companies' joint activities aiming to improve different aspects of life here. For years, responsible business has been investing in projects which are important not only for itself and for parties involved with it, but also for the public, as they strive for social resilience and change.

Sopharma AD  notifies that on 23.02.2018 an Extraordinary general meeting of shareholders took place.

The General meeting of shareholders approved the decision for transformation of Sopharma AD, UIC: 831902088 by merging Unipharm AD, UIC: 831537465 into it. As a result of the merger, the entire property of Unipharm AD, UIC: 831537465 will be transferred to Sopharma AD, UIC: 831902088 under the conditions of general succession.

Credit: ELANA Trading

Sopharma’s (3JR BU) smoking cessation drug with positive preliminary clinical trial data in the US, the Company’s American partner Achieve Life Sciences (NASDAQ: ACHV) announced in a statement.

Sopharma AD notifies that on 29 December 2017 the Company bought 1186 own shares representing 0.00088% of the share capital of the Company, at a total value of 5080.82 BGN on the Bulgarian Stock Exchange, the average price per share was 4.28 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 8 904 000, representing 6.61% of the share capital of the Company.

Sopharma AD notifies that for January 2018 the Company recorded an increase of sales revenues of 3% compared to the same month of 2017, including 5% increase of export sales and same level of domestic sales.

Sopharma AD ended its most successful financial year after the crisis. 2017 ended with 12.5% revenue growth reaching 205.3 million BGN, 44.8% increase in operating profit, 30.7% EBITDA growth and almost 10% growth in net profit.

During this successful year, the company took two important investment decisions, namely to start the construction of:

1. An extraction plant in Kazanlak, which will allow more effective and modern production of all phyto products and

Sopharma AD received a notification for the sale of 250 000 shares, representing 0.19% of its capital, by CUPF Allianz Bulgaria. After the transaction the share of CUPF Allianz Bulgaria in the capital of Sopharma AD reached 4.99%.

The date of the registration of the transaction with the Central Depository is 24 January 2018.